ArticleHuman genomics2026
HMGCR genetic variation and risk of new-onset type 2 diabetes in statin users.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundStatins are widely prescribed lipid-lowering agents, but their use is associated with an increased risk of new-onset type 2 diabetes mellitus (NO-T2DM) ranging from 9% to 13%. While genetic variants in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the pharmacological target of statins, and the solute carrier organic anion transporter family, member 1B1 (SLCO1B1), a key hepatic transporter, have been implicated in statin response and toxicity, their role in statin-associated diabetogenesis remains unclear.
objectiveTo investigate the association of four common HMGCR variants (rs17671591, rs12916, rs17238484, and rs2303152) and the SLCO1B1 (rs4149056) with the risk of NO-T2DM among statin-treated cohort.
methodsIn a matched case-control study, 194 adults receiving atorvastatin or rosuvastatin were enrolled. The cases were patients who developed NO-T2DM within four years of initiating statin therapy (n = 97), while controls remained diabetes-free after four years of use (n = 97). Participants were matched for age, sex, ethnicity, BMI, and statin intensity. Genotyping was performed using TaqMan assays, and associations were evaluated using genetic models, linkage disequilibrium (LD), and haplotype analyses.
resultsThe HMGCR rs17238484 variant showed a nominal association with NO-T2DM in statin users. Carriers of the T allele (GT + TT) showed a lower risk compared with the GG genotype (OR = 0.56, 95% CI: 0.36–0.99, P = 0.044); however, this association did not remain significant after correction for multiple testing. Haplotype analysis identified that the T–T–T haplotype of rs17671591–rs17238484–rs12916 was significantly associated with reduced risk of NO-T2DM (OR = 0.12, 95% CI: 0.02–0.58, P = 0.009). Other HMGCR SNPs and SLCO1B1 rs4149056 showed no significant associations.
conclusionThese findings suggest that HMGCR haplotypes may be associated with NO-T2DM risk among statin users, further studies in larger and more diverse populations are needed to validate these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.